SISAQOL-IMI - Setting international standars in the analysis of patient reported outcomes and health related quality of life data in cancer clinical trials

SISAQOL-IMI
SISAQOL-IMI
International Projects
Project management unit
SISAQOL-IMI - Setting international standars in the analysis of patient reported outcomes and health related quality of life data in cancer clinical trials

SISAQOL-IMI (945042  - Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI) is an international multidisciplinary consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI). The consortium has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient reported outcome (PRO) data in cancer clinical trials.

SISAQOL-IMI will establish guidance on how to use patient-reported outcomes in cancer clinical trials so that they can be used in a methodologically sound way, analysed in a statistically adequate manner, and intelligibly presented to ensure a high study quality and a better comparability of results across clinical trials.

In june 2023, The Lancet - Oncology Magazine publishes the article: Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.

Web
Funding organisation
Data sheet
Financing
Internacional
Organisation
European Commission
Start - End
-
Centre
Fundación Pública Miguel Servet
Researchers